Latest Content

Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer

February 20th 2025, 10:00pm

By Spencer Feldman

Article

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC

February 20th 2025, 8:05pm

By Ashling Wahner

Article

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

How Pets Can Provide Hope for Patients With Bladder Cancer

February 20th 2025, 6:00pm

By Chester Freeman

Article

My pet provided emotional support and helped me tolerate chemotherapy better, reducing my stress and improving my well-being throughout my cancer journey.

Personalized Cancer Vaccine Demonstrates Responses in Kidney Cancer

February 20th 2025, 5:00pm

By Dr. Catherine Wu

Video

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.

Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer

February 20th 2025, 4:00pm

By Dr. Nataliya Uboha

Video

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

February 20th 2025, 2:00pm

By Jax DiEugenio

Article

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

February 19th 2025, 10:00pm

By Jax DiEugenio

Article

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

February 19th 2025, 8:00pm

By Ryan Scott

Article

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

Navigating Time and Emotions After Testicular Cancer

February 19th 2025, 6:00pm

By Brian Sluga

Article

I often reflect on my emotional changes following a testicular cancer diagnosis and how I learned to manage them and grow.

Explaining PROs From the TiNivo-2 Study in Advanced Renal Cell Carcinoma

February 19th 2025, 5:00pm

By Dr. Katy Beckermann

Video

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

What Patients With Cancer Need to Know About Counterfeit Drugs Risk

February 19th 2025, 4:00pm

By Alex Biese

Article

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

SBRT May Be Superior to Radiofrequency Ablation in Liver Cancer

February 19th 2025, 2:00pm

By Spencer Feldman

Article

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

February 18th 2025, 10:00pm

By Ashling Wahner

Article

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma

February 18th 2025, 8:00pm

By Alex Biese

Article

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

The Good and The Bad of Follicular Lymphoma

February 18th 2025, 6:00pm

By Karen Cohn

Article

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.